MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) Short Interest Up 38.9% in March

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) was the recipient of a significant increase in short interest in the month of March. As of March 15th, there was short interest totalling 980,100 shares, an increase of 38.9% from the February 28th total of 705,700 shares. Based on an average daily volume of 352,300 shares, the days-to-cover ratio is presently 2.8 days. Currently, 8.0% of the company’s shares are sold short.

MIRA Pharmaceuticals Stock Down 2.6 %

Shares of NASDAQ MIRA opened at $0.96 on Wednesday. The firm’s fifty day moving average is $1.12 and its 200 day moving average is $1.22. MIRA Pharmaceuticals has a 52 week low of $0.51 and a 52 week high of $5.01. The company has a market cap of $15.82 million, a price-to-earnings ratio of -1.71 and a beta of 2.31.

MIRA Pharmaceuticals (NASDAQ:MIRA) last announced its quarterly earnings results on Friday, March 28th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.14. Equities research analysts anticipate that MIRA Pharmaceuticals will post -0.6 earnings per share for the current year.

Institutional Investors Weigh In On MIRA Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the business. International Assets Investment Management LLC purchased a new position in MIRA Pharmaceuticals during the 4th quarter valued at $29,000. Virtu Financial LLC bought a new stake in shares of MIRA Pharmaceuticals during the 4th quarter valued at about $72,000. Renaissance Technologies LLC purchased a new position in shares of MIRA Pharmaceuticals during the fourth quarter valued at about $52,000. Northern Trust Corp raised its stake in MIRA Pharmaceuticals by 50.9% in the fourth quarter. Northern Trust Corp now owns 30,362 shares of the company’s stock worth $35,000 after buying an additional 10,238 shares in the last quarter. Finally, Citadel Advisors LLC purchased a new stake in MIRA Pharmaceuticals in the fourth quarter worth about $112,000. Hedge funds and other institutional investors own 35.16% of the company’s stock.

About MIRA Pharmaceuticals

MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.